Menu
Search
|

Menu

Close
X

CohBar Inc CWBR.OQ (NASDAQ Stock Exchange Capital Market)

1.44 USD
-0.00 (-0.00%)
As of 4:00 PM EDT
Previous Close 1.44
Open 1.41
Volume 2,190
3m Avg Volume 36,860
Today’s High 1.44
Today’s Low 1.41
52 Week High 4.89
52 Week Low 1.26
Shares Outstanding (mil) 42.78
Market Capitalization (mil) 66.31
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
0
FY17
0
FY16
0
EPS (USD)
FY19
-0.068
FY18
-0.380
FY17
-0.261
FY16
-0.183
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.85
Price to Sales (TTM)
vs sector
--
7.90
Price to Book (MRQ)
vs sector
4.13
4.38
Price to Cash Flow (TTM)
vs sector
--
23.70
Total Debt to Equity (MRQ)
vs sector
18.90
17.64
LT Debt to Equity (MRQ)
vs sector
18.90
12.61
Return on Investment (TTM)
vs sector
-111.82
12.69
Return on Equity (TTM)
vs sector
-133.85
17.13

EXECUTIVE LEADERSHIP

Albion Fitzgerald
Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
Steven Engle
Chief Executive Officer, Director, Since 2019
Salary: --
Bonus: --
Jeffrey Biunno
Chief Financial Officer, Treasurer, Secretary, Since 2014
Salary: $200,000.00
Bonus: $50,000.00
Jon Stern
Chief Operating Officer, Director, Since 2016
Salary: $195,082.00
Bonus: $65,625.00
Kenneth Cundy
Chief Scientific Officer, Since 2014
Salary: $28,846.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1455 Adams Dr Ste 2050
MENLO PARK   CA   94025-1438

Phone: +1650.4467888

CohBar, Inc. (CohBar) is engaged in the research and development of mitochondria-based therapeutics (MBTs), a class of drugs with potential for the treatment of diseases associated with aging. MBTs originate from the discovery of a group of peptides encoded within the genome of mitochondria. The Company's development of mitochondrial-derived peptides (MDPs) into MBTs offers the potential to address a range of diseases including type 2 diabetes, cancer, atherosclerosis and neurodegenerative disorders. MDPs represent a diverse and largely unexplored collection of peptides. MOTS-c is an MDP, which indicates that it plays a role in the regulation of metabolism. The Company is engaged in the research on MOTS-c and its analogs as its lead program. The Company's academic collaborators have discovered various other MDPs with similar mitochondrial origin to the MDP, humanin, which the Company refers to as small humanin-like peptides (SHLPs).

SPONSORED STORIES